Resource Type

Journal Article 8

Year

2022 2

2021 2

2020 1

2019 1

2017 1

2015 1

Keywords

CAR T cells 2

hematological malignancies 2

Fanconi anemia 1

IRF4 1

IRF8 1

adverse events 1

allogeneic hematopoietic stem cell transplantation 1

aplastic anemia 1

biomarker 1

bone marrow infiltration 1

chemotherapy 1

clonal T-cell population 1

diagnosis 1

endogenous immune response 1

essential thrombocythemia 1

gastrectomy 1

gastric carcinoma 1

gastrointestinal fluid 1

germline predisposition 1

hematologic malignancy 1

open ︾

Search scope:

排序： Display mode:

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 783-804 doi: 10.1007/s11684-021-0904-z

Abstract: The current standard of care in hematological malignancies has brought considerable clinical benefitsof tumor clones cause difficulty in ensuring long-term efficacy of conventional treatments for most hematologicalChimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematologicalmalignancies.

Keywords： CAR T cells     hematological malignancies     review    

HTML PDF Collect

Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoingchemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study

Ling Wang, Ying Wang, Jiong Hu, Yuqian Sun, He Huang, Jing Chen, Jianyong Li, Jun Ma, Juan Li, Yingmin Liang, Jianmin Wang, Yan Li, Kang Yu, Jianda Hu, Jie Jin, Chun Wang, Depei Wu, Yang Xiao, Xiaojun Huang

Frontiers of Medicine 2019, Volume 13, Issue 3,   Pages 365-377 doi: 10.1007/s11684-018-0641-0

Abstract: Invasive fungal disease (IFD) is a major infectious complication in patients with hematological malignanciesIn this study, we examined 4889 courses of chemotherapy in patients with hematological diseases to establish

Keywords： invasive fungal diseases     hematological malignancies     chemotherapy     risk score     prophylaxis    

HTML PDF Collect

cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies

Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu

Frontiers of Medicine 2021, Volume 15, Issue 1,   Pages 108-115 doi: 10.1007/s11684-019-0730-8

Abstract: Improved survival rate was reported in lymphoid malignancies following PT-Cy strategy compared with myeloidafter myeloablative conditioning and T cell-replete peripheral stem cell transplantation in lymphoid malignancies

Keywords： post-transplantation cyclophosphamide     allogeneic hematopoietic stem cell transplantation     lymphoid malignancies    

HTML PDF Collect

Detection of digestive malignancies and post-gastrectomy complications via gastrointestinal fluid examination

Lei Huang,Aman Xu

Frontiers of Medicine 2017, Volume 11, Issue 1,   Pages 20-31 doi: 10.1007/s11684-016-0493-4

Abstract:

To date, gastric carcinoma (GC) is one of the common and fatal digestive malignancies worldwide.

Keywords： gastrointestinal fluid     gastric carcinoma     biomarker     diagnosis     prognosis     gastrectomy     adverse events    

HTML PDF Collect

IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 403-415 doi: 10.1007/s11684-021-0858-1

Abstract: The morbidity and mortality of myeloproliferative neoplasms (MPNs) are primarily caused by arterial and venous complications, progression to myelofibrosis, and transformation to acute leukemia. However, identifying molecular-based biomarkers for risk stratification of patients with MPNs remains a challenge. We have previously shown that interferon regulatory factor-8 (IRF8) and IRF4 serve as tumor suppressors in myeloid cells. In this study, we evaluated the expression of IRF4 and IRF8 and the JAK2V617F mutant allele burden in patients with MPNs. Patients with decreased IRF4 expression were correlated with a more developed MPN phenotype in myelofibrosis (MF) and secondary AML (sAML) transformed from MPNs versus essential thrombocythemia (ET). Negative correlations between the JAK2V617F allele burden and the expression of IRF8 (P <0.05) and IRF4 (P<0.001) and between white blood cell (WBC) count and IRF4 expression (P <0.05) were found in ET patients. IRF8 expression was negatively correlated with the JAK2V617F allele burden (P <0.05) in polycythemia vera patients. Complete response (CR), partial response (PR), and no response (NR) were observed in 67.5%, 10%, and 22.5% of ET patients treated with hydroxyurea (HU), respectively, in 12 months. At 3 months, patients in the CR group showed high IRF4 and IRF8 expression compared with patients in the PR and NR groups. In the 12-month therapy period, low IRF4 and IRF8 expression were independently associated with the unfavorable response to HU and high WBC count. Our data indicate that the expression of IRF4 and IRF8 was associated with the MPN phenotype, which may serve as biomarkers for the response to HU in ET.

Keywords： myeloproliferative neoplasms     IRF4     IRF8     hydroxyurea     essential thrombocythemia    

HTML PDF Collect

Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies:

Wen Xue,Yan Sheng,Xiangqin Weng,Yongmei Zhu,Yan Zhao,Pengpeng Xu,Xiaochun Fei,Xiaoyan Chen,Li Wang,Weili Zhao

Frontiers of Medicine 2015, Volume 9, Issue 4,   Pages 468-477 doi: 10.1007/s11684-015-0419-6

Abstract:

Mature T-cell lymphoid malignancies comprise a group of heterogeneous diseases that vary in clinicopathologicalBone marrow (BM) infiltration is more commonly present in mature T-cell lymphoid malignancies comparedclinical characteristics and prognostic factors were analyzed in 225 patients with mature T-cell lymphoid malignanciescharacteristics may be useful in more effectively stratifying patients with mature T-cell lymphoid malignancies

Keywords： mature T-cell lymphoid malignancies     clonal T-cell population     bone marrow infiltration     prognostic factors    

HTML PDF Collect

Fanconi anemia gene-associated germline predisposition in aplastic anemia and hematologic malignancies

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 459-466 doi: 10.1007/s11684-021-0841-x

Abstract: Whether Fanconi anemia (FA) heterozygotes are predisposed to bone marrow failure and hematologic neoplasm is a crucial but unsettled issue in cancer prevention and family consulting. We retrospectively analyzed rare possibly significant variations (PSVs) in the five most obligated FA genes, BRCA2, FANCA, FANCC, FANCD2, and FANCG, in 788 patients with aplastic anemia (AA) and hematologic malignancy. Sixty-eight variants were identified in 66 patients (8.38%). FANCA was the most frequently mutated gene (n = 29), followed by BRCA2 (n = 20). Compared with that of the ExAC East Asian dataset, the overall frequency of rare PSVs was higher in our cohort (P = 0.016). BRCA2 PSVs showed higher frequency in acute lymphocytic leukemia (P = 0.038), and FANCA PSVs were significantly enriched in AA and AML subgroups (P = 0.020; P = 0.008). FA-PSV-positive MDS/AML patients had a higher tumor mutation burden, higher rate of cytogenetic abnormalities, less epigenetic regulation, and fewer spliceosome gene mutations than those of FA-PSV-negative MDS/AML patients (P = 0.024, P = 0.029, P = 0.024, and P = 0.013). The overall PSV enrichment in our cohort suggests that heterozygous mutations of FA genes contribute to hematopoietic failure and leukemogenesis.

Keywords： Fanconi anemia     aplastic anemia     hematologic malignancy     germline predisposition    

HTML PDF Collect

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 726-745 doi: 10.1007/s11684-020-0746-0

Abstract: However, CAR T cells have achieved minimal success against solid malignancies because of the additionalrecent advances in the engineering of CAR T cell therapies to restore the immune response in solid malignancies

Keywords： CAR T cells     immunoregulatory molecules     endogenous immune response     solid malignancies    

HTML PDF Collect

Title Author Date Type Operation

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Journal Article

Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoingchemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study

Ling Wang, Ying Wang, Jiong Hu, Yuqian Sun, He Huang, Jing Chen, Jianyong Li, Jun Ma, Juan Li, Yingmin Liang, Jianmin Wang, Yan Li, Kang Yu, Jianda Hu, Jie Jin, Chun Wang, Depei Wu, Yang Xiao, Xiaojun Huang

Journal Article

cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies

Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu

Journal Article

Detection of digestive malignancies and post-gastrectomy complications via gastrointestinal fluid examination

Lei Huang,Aman Xu

Journal Article

IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to

Journal Article

Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies:

Wen Xue,Yan Sheng,Xiangqin Weng,Yongmei Zhu,Yan Zhao,Pengpeng Xu,Xiaochun Fei,Xiaoyan Chen,Li Wang,Weili Zhao

Journal Article

Fanconi anemia gene-associated germline predisposition in aplastic anemia and hematologic malignancies

Journal Article

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han

Journal Article